Compare CZNC & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZNC | VOGX |
|---|---|---|
| Founded | 1864 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.4M | 456.5M |
| IPO Year | 2009 | 2026 |
| Metric | CZNC | VOGX |
|---|---|---|
| Price | $25.74 | $29.80 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $23.50 | N/A |
| AVG Volume (30 Days) | 59.8K | ★ 212.4K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.87 | $14.80 |
| 52 Week High | $26.26 | $35.50 |
| Indicator | CZNC | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 81.95 |
| Support Level | $25.00 | $27.37 |
| Resistance Level | $26.12 | $35.06 |
| Average True Range (ATR) | 0.46 | 4.37 |
| MACD | -0.07 | -0.15 |
| Stochastic Oscillator | 51.20 | 67.31 |
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.